Pharmaceutical

AC Immune wins FDA fast track for Alzheimer’s vaccine candidate

JNJ-2056 is being investigated in the Phase IIb ReTain study which enrols participants who are yet to show Alzheimer’s symptoms.

Jul 26, 2024 - 04:00
AC Immune wins FDA fast track for Alzheimer’s vaccine candidate
JNJ-2056 is being investigated in the Phase IIb ReTain study which enrols participants who are yet to show Alzheimer’s symptoms.
Read the original article

Tags:

Previous Article

Rainfall patterns have become more erratic over the past century: Solid evidence...

Next Article

Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion

STAT+: Merck, Daiichi Sankyo to partner on targeted che...

Oct 20, 2023

Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro

Pfizer’s twice daily pill for obesity hopes to rival We...

Oct 26, 2023

ADCs breach barriers to become mainstream cancer treatment

ADCs breach barriers to become mainstream cancer treatment

Dec 17, 2024